Skin Aging, Dry SkinNCT07486414
Efficacy and Safety of NP-2007 on Skin Health
A study testing NP-2007 in people with Skin Aging, Dry Skin, run by Hanpoong Nature Pharm Co., Ltd. at 1 site in South Korea.
Trial summary
The objective of this study is to evaluate the efficacy and safety of Small-molecular-weight deer antler collagen (NP-2007) on skin health, including skin hydration, transepidermal water loss (TEWL), elasticity, and eye wrinkles. Read more about this study
- Who is it for?
- Ages 35 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Skin Aging, Dry Skin
- What is being tested?
- NP-2007
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 84 participants
- Where
- 1 siteSouth Korea
- Study dates
- 4 Apr 2022to 30 Sep 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy females between 35 and 65 years of age
- Subjects with dry skin (Skin capacitance ≤ 49 units measured by Corneometer® CM 825)
- Subjects with eye wrinkles (grade 3 or higher based on visual assessment scale)
- Subjects who voluntarily signed the informed consent form after receiving a full explanation of the study
- Subjects who are available for follow-up visits at scheduled times throughout the study period
Who cannot join
- 1) Subjects with skin diseases (atopic dermatitis, psoriasis, etc.) in the test area
- 2) Subjects who have used skin-related medications (steroids, etc.) within 1 month
- 3) Subjects with a history of hypersensitivity to the test ingredients or severe food allergies
- 4) Pregnant or lactating women, or those planning to become pregnant
- 5) Subjects who have participated in other clinical trials within the past 3 months
- 6) Any other conditions that the investigator deems unsuitable for participation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A 12-week, Randomized, Double-Blind, Placebo-Controlled Human Clinical Study to Evaluate the Efficacy and Safety of Small-Molecular-Weight Deer Antler Collagen (NP-2007) for Improving Skin Health
The objective of this study is to evaluate the efficacy and safety of Small-molecular-weight deer antler collagen (NP-2007) on skin health, including skin hydration, transepidermal water loss (TEWL), elasticity, and eye wrinkles.
- Conditions
- Skin Aging, Dry Skin
- Being tested
- NP-2007, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NP-2007Dietary supplement
500mg/day, once a day, take 2 tablets with water.
PlaceboDietary supplement
Take 2 tablets (matching NP-2007) once a day with water.
| Study group | Role | What they receive |
|---|---|---|
| NP-2007 | Experimental | 500mg/day, once a day, take 2 tablets with water. Receives: Dietary Supplement: NP-2007 |
| Placebo | Placebo comparator | Take 2 tablets (matching NP-2007) once a day with water. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Skin Hydration at 12 weeks
Measured using Corneometer® CM 825. The unit of measure is arbitrary units (AU) ranging from 0 to 120. Higher scores indicate improved skin moisture.
Measured: Baseline, 6 weeks, 12 weeks
Change from Baseline in Transepidermal Water Loss (TEWL) at 12 Weeks
Measured using Tewameter® TM 300. The unit of measure is g/m²/h. Lower values indicate improved skin barrier function.
Measured: Baseline, 6 weeks, 12 weeks
Change from Baseline in Skin Scaling at 12 Weeks
Evaluated using D-Squame® and image analysis. Higher values indicate more scaling (worse), lower values indicate improvement.
Measured: Baseline, 6 weeks, 12 weeks
Change from Baseline in Skin Roughness at 12 Weeks
Measured using Visiometer® SV 700. Assesses the texture of the skin surface. Lower values indicate smoother skin.
Measured: Baseline, 6 weeks, 12 weeks
Change from Baseline in Eye Wrinkles (Ra) at 12 Weeks
Quantitative analysis of eye wrinkles (crow's feet) using Visiometer® SV 700. Ra represents the average roughness in millimeters (mm). Lower values indicate improved wrinkle depth.
Measured: Baseline, 6 weeks, 12 weeks
Change from Baseline in Skin Elasticity (R2) at 12 Weeks
Measured using Cutometer® MPA 580. R2 represents gross elasticity (0 to 1 scale). Higher values indicate better skin elasticity.
Measured: Baseline, 6 weeks, 12 weeks
Secondary outcomes (2)
Investigator's Visual Assessment Grade for Eye Wrinkles
Baseline, 6 weeks, 12 weeks Clinical grading of eye wrinkle severity by a dermatologist using a visual analog scale. The scale ranges from 0 to 9, where 0 indicates 'None' (no wrinkles) and 9 indicates 'Very Severe' wrinkles. A decrease in the score (lower values) represents a better outcome (improvement in wrinkles).
Measured: Clinical grading of eye wrinkle severity by a dermatologist. The grade is based on a visual scale from 0 to 9 (0 = None, 9 = Very Severe). Lower grades indicate clinical improvement in wrinkle severity.
Participant Subjective Questionnaire Assessment for Skin Improvement
6 weeks, 12 weeks Participants' self-assessment of skin improvement using a 5-point Likert scale. The scale ranges from 1 to 5, where 1 indicates 'Very Dissatisfied' and 5 indicates 'Very Satisfied'. A higher score represents a better outcome (higher satisfaction and perceived efficacy).
Measured: Participants assess skin improvement and satisfaction through a self-report questionnaire using a 5-point Likert scale (1 = Very Dissatisfied, 5 = Very Satisfied). Higher scores indicate greater satisfaction with the product's efficacy.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2026
- Study start4 Apr 2022
- Primary completion15 Jul 2022
- Study completion30 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Skin Aging, Dry SkinStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 84 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hanpoong Nature Pharm Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07486414
- Sponsor's protocol ID
- NP2007_HPN
- Status last verified
- Mar 2026
- First submitted
- 13 Mar 2026
- Last updated
- 20 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 12-week, Randomized, Double-Blind, Placebo-Controlled Human Clinical Study to Evaluate the Efficacy and Safety of Small-Molecular-Weight Deer Antler Collagen (NP-2007) for Improving Skin Health
- ClinicalTrials.gov ID
- NCT07486414
- Acronym / sponsor ID
- NP2007_HPN
- Conditions
- Skin Aging, Dry Skin
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 84 participants (actual)
- Lead sponsor
- Hanpoong Nature Pharm Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 4 Apr 2022 (actual)
- Primary completion
- 15 Jul 2022 (actual)
- Study completion
- 30 Sep 2022 (actual)
- First posted
- 20 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to evaluate the efficacy and safety of Small-molecular-weight deer antler collagen (NP-2007) on skin health, including skin hydration, transepidermal water loss (TEWL), elasticity, and eye wrinkles.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| NP-2007 | Experimental | Dietary Supplement: NP-2007500mg/day, once a day, take 2 tablets with water. |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboTake 2 tablets (matching NP-2007) once a day with water. |
Who may qualify
- Ages
- 35 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Healthy females between 35 and 65 years of age
- Subjects with dry skin (Skin capacitance ≤ 49 units measured by Corneometer® CM 825)
- Subjects with eye wrinkles (grade 3 or higher based on visual assessment scale)
- Subjects who voluntarily signed the informed consent form after receiving a full explanation of the study
- Subjects who are available for follow-up visits at scheduled times throughout the study period
Key exclusion criteria (6 listed)
- 1) Subjects with skin diseases (atopic dermatitis, psoriasis, etc.) in the test area
- 2) Subjects who have used skin-related medications (steroids, etc.) within 1 month
- 3) Subjects with a history of hypersensitivity to the test ingredients or severe food allergies
- 4) Pregnant or lactating women, or those planning to become pregnant
- 5) Subjects who have participated in other clinical trials within the past 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NP-2007500mg/day, once a day, take 2 tablets with water. | Dietary supplement | NP-2007 |
| PlaceboTake 2 tablets (matching NP-2007) once a day with water. | Dietary supplement | Placebo |
Primary outcome
Change from Baseline in Skin Hydration at 12 weeks
Time frame: Baseline, 6 weeks, 12 weeks
Measured using Corneometer® CM 825. The unit of measure is arbitrary units (AU) ranging from 0 to 120. Higher scores indicate improved skin moisture.
Change from Baseline in Transepidermal Water Loss (TEWL) at 12 Weeks
Time frame: Baseline, 6 weeks, 12 weeks
Measured using Tewameter® TM 300. The unit of measure is g/m²/h. Lower values indicate improved skin barrier function.
Change from Baseline in Skin Scaling at 12 Weeks
Time frame: Baseline, 6 weeks, 12 weeks
Evaluated using D-Squame® and image analysis. Higher values indicate more scaling (worse), lower values indicate improvement.
Change from Baseline in Skin Roughness at 12 Weeks
Time frame: Baseline, 6 weeks, 12 weeks
Measured using Visiometer® SV 700. Assesses the texture of the skin surface. Lower values indicate smoother skin.
Change from Baseline in Eye Wrinkles (Ra) at 12 Weeks
Time frame: Baseline, 6 weeks, 12 weeks
Quantitative analysis of eye wrinkles (crow's feet) using Visiometer® SV 700. Ra represents the average roughness in millimeters (mm). Lower values indicate improved wrinkle depth.
Change from Baseline in Skin Elasticity (R2) at 12 Weeks
Time frame: Baseline, 6 weeks, 12 weeks
Measured using Cutometer® MPA 580. R2 represents gross elasticity (0 to 1 scale). Higher values indicate better skin elasticity.
2 secondary outcomes
Investigator's Visual Assessment Grade for Eye Wrinkles
Time frame: Clinical grading of eye wrinkle severity by a dermatologist. The grade is based on a visual scale from 0 to 9 (0 = None, 9 = Very Severe). Lower grades indicate clinical improvement in wrinkle severity.
Participant Subjective Questionnaire Assessment for Skin Improvement
Time frame: Participants assess skin improvement and satisfaction through a self-report questionnaire using a 5-point Likert scale (1 = Very Dissatisfied, 5 = Very Satisfied). Higher scores indicate greater satisfaction with the product's efficacy.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2026.
Related trials for Skin Aging, Dry Skin
Not yet recruiting
Effects of Probiotics on Skin Health in Healthy Women
Skin Aging, Dry Skin
Active, not recruiting
Efficacy and Safety of a Topical Botanical Extract Formulation for Skin Aging
Aging, Dry Skin
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing NP-2007 in people with Skin Aging, Dry Skin, run by Hanpoong Nature Pharm Co., Ltd. at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in Skin Hydration at 12 weeks (time frame: Baseline, 6 weeks, 12 weeks). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2026.